Pain has really been out of favor in the industry up until very recently,” said John Mulcahy, SiteOne Therapeutics’ CEO. The ...

News of Merck’s licensing of Hansoh’s preclinical medicine pressured shares in Viking and other obesity drug developers seen ...

The Bill & Melinda Gates Foundation will invest up to $50 million in Tessera’s in vivo sickle cell therapy. Elsewhere, Cara ...

Lawmakers on Tuesday released the text of a bipartisan agreement to fund the government through March. It could reshape the pharmacy supply chain by reforming how drug middlemen do business.

Bumpus replaced agency veteran Janet Woodcock as principal deputy commissioner in February 2024. She was previously the FDA’s ...

Phase 2 results in inflammatory bowel disease hinted the therapy could be more potent than similar medicines from Merck and ...

The company forecast revenue next year will grow slightly versus this year, when excluding certain factors. “The uncertainty ...

An FDA approval of Merck’s drug clesrovimab by June would give physicians another option for protecting newborns from respiratory syncytial virus.

On the other hand, culturing cells under physiological, hypoxic conditions can offer therapeutic benefits. Indeed, hypoxic ...

The pharma will pay $200 million to buy Nimble and a preclinical oral drug that blocks a protein known as IL-23 — the target ...

The company is scrapping two drugs aimed at targets called TIGIT and LAG-3, both of which were in the middle of Phase 3 ...

Bruce Cozadd, who co-founded the company two decades ago, will step down once a successor is found. Jazz aims to complete its ...